Canada: First Subject Treated in Vancouver Study

On February 3, 2015, the first subject received their first experimental treatment in our Canadian study of MDMA-assisted psychotherapy for PTSD. The purpose of this small Phase 2 study in up to 12 subjects with chronic, treatment-resistant PTSD is to train and gather outcsome data from a new team of co-therapists, and lay the groundwork for a potential Phase 3 study site. This study has been in preparation for over eight years, since we began working on this project near the end of 2006. This is the first Health Canada-approved clinical psychedelic research to take place in over 40 years. “We are excited and inspired to finally start the clinical phase of the Vancouver MDMA/PTSD study,” wrote Sub-Investigator Donna Dryer, MD, FRCPC. “We are honored and proud to realize our dream with MAPS in Canada, the country that originally launched psychedelic therapy in the 1950s!”